Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immatics (IMTX – Research Report) today and set a price target of $25.00. The company’s shares closed today at $11.60.
Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, 4D Molecular Therapeutics, and Krystal Biotech. According to TipRanks, Livshits has an average return of 26.6% and a 40.05% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immatics with a $25.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $13.60 and a one-year low of $5.90. Currently, Immatics has an average volume of 432.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company’s pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
Read More on IMTX:
- Immatics Announces Second Quarter 2023 Financial Results and Business Update
- Immatics initiates Phase 1/2 trial to evaluate PRAME TCR bispecific IMA402
- Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
- Immatics (NASDAQ:IMTX) Gains on Equity Infusion by Bristol-Myers Squibb (NYSE:BMY)
- Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
